GLP-1 RAs Linked to Higher Hair Loss Risk
A large matched cohort study quantifies the association between glucagon-like peptide-1 receptor agonist use and nonscarring alopecia
By
Kerri Miller
February 19, 2026
Clinical Scorecard: GLP-1 RAs Linked to Higher Hair Loss Risk
At a Glance
Category Detail
Condition Nonscarring hair loss associated with GLP-1 receptor agonists Key Mechanisms Rapid weight loss, alterations in insulin signaling, androgen changes, direct follicular effects Target Population Adults aged 18 to 89 years and adolescents aged 12 to 17 years treated with GLP-1 RAs Care Setting Multicenter cohort study using electronic health records
Key Highlights
GLP-1 RA users had higher odds of nonscarring hair loss at 6 and 12 months compared to controls. At 12 months, odds ratios for telogen effluvium, androgenetic alopecia, and overall hair loss were significant. Adolescents showed limited data due to small sample size, highlighting access barriers. Guideline-Based Recommendations
Diagnosis
Monitor for nonscarring hair loss in patients prescribed GLP-1 RAs. Management
Provide anticipatory guidance regarding hair loss risks. Monitoring & Follow-up
Consider prospective monitoring strategies for hair loss in patients on GLP-1 RAs. Risks
Increased odds of telogen effluvium and androgenetic alopecia in GLP-1 RA users. Patient & Prescribing Data
Adults and adolescents using GLP-1 RAs for type 2 diabetes management.
Awareness of alopecia risk is critical for early detection and multidisciplinary care.
Clinical Best Practices
Educate patients on potential hair loss associated with GLP-1 RA therapy. Encourage regular follow-ups to assess hair health in patients on GLP-1 RAs. Related Resources & Content
